Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bone health 2022: an update.
de Villiers TJ, Goldstein SR. de Villiers TJ, et al. Climacteric. 2022 Feb;25(1):1-3. doi: 10.1080/13697137.2021.1965408. Climacteric. 2022. PMID: 35041568 No abstract available.
Osteoporosis management in hematologic stem cell transplant recipients: Executive summary.
Kendler DL, Body JJ, Brandi ML, Broady R, Cannata-Andia J, Cannata-Ortiz MJ, El Maghraoui A, Guglielmi G, Hadji P, Pierroz DD, de Villiers TJ, Ebeling PR, Rizzoli R. Kendler DL, et al. Among authors: de villiers tj. J Bone Oncol. 2021 Apr 23;28:100361. doi: 10.1016/j.jbo.2021.100361. eCollection 2021 Jun. J Bone Oncol. 2021. PMID: 33996429 Free PMC article. Review.
Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis.
Saag KG, de Villiers TJ, Alexandersen P, Jacobe H, Kovarik C, Werth VP, Leung A, Desai-Merchant A, Mattaliano J, Gurner D. Saag KG, et al. Among authors: de villiers tj. J Am Acad Dermatol. 2021 Apr;84(4):1113-1119. doi: 10.1016/j.jaad.2020.06.036. Epub 2020 Jun 15. J Am Acad Dermatol. 2021. PMID: 32553680 Clinical Trial. No abstract available.
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS; LOFT Investigators. McClung MR, et al. Lancet Diabetes Endocrinol. 2019 Dec;7(12):899-911. doi: 10.1016/S2213-8587(19)30346-8. Epub 2019 Oct 31. Lancet Diabetes Endocrinol. 2019. PMID: 31676222 Clinical Trial.
Effects of ospemifene on bone in postmenopausal women.
de Villiers TJ, Altomare C, Particco M, Gambacciani M. de Villiers TJ, et al. Climacteric. 2019 Oct;22(5):442-447. doi: 10.1080/13697137.2019.1631789. Epub 2019 Jul 11. Climacteric. 2019. PMID: 31294631
Bone management in hematologic stem cell transplant recipients.
Kendler DL, Body JJ, Brandi ML, Broady R, Cannata-Andia J, Cannata-Ortiz MJ, El Maghraoui A, Guglielmi G, Hadji P, Pierroz DD, de Villiers TJ, Rizzoli R, Ebeling PR; International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer and Bone Disease. Kendler DL, et al. Among authors: de villiers tj. Osteoporos Int. 2018 Dec;29(12):2597-2610. doi: 10.1007/s00198-018-4669-4. Epub 2018 Sep 3. Osteoporos Int. 2018. PMID: 30178158 Review.
59 results